No Data
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule Α4β7 Inhibition of Gut-Trafficking Cells
Supporting Materials: Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclona... Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclona...-α4
Morphic Ethical Funds Continues Share Buy-Back
The constituent stocks MacroGenics closed down 14.75%, Scholar Rock, Morphic Holding, Novavax Pharmaceuticals (NVAX), and Travere Therapeutics fell 12.78%-9.42%; while MyGN (MYGN) closed up 2.76%, Wave Life Sciences, Erasca, Nurix, and Autolus Therapeutic
The constituent stocks MacroGenics closed down 14.75%, Scholar Rock, Morphic Holding, Novavax Pharmaceuticals (NVAX), and Travere Therapeutics fell 12.78%-9.42%; while MyGN (MYGN) closed up 2.76%, Wave Life Sciences, Erasca, Nurix, and Autolus Therapeutics rose 6.10%-7.86%.
Morphic Fund's Buyback Plan Wins Strong Approval
Morphic Fund Announces Upcoming Dividend
Morphic Fund Navigates Ethical Investing Amid Market Volatility